Drug Trial Radar · NCT04809376
Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain
Last checked: Nov 19, 2026Latest source record: Apr 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
602
Actual
Start
Oct 19, 2021
Primary completion
Oct 15, 2024
Study completion Jan 6, 2025
Sponsor
- Lead sponsor
- Paradigm Biopharmaceuticals USA (INC)Industry
- Sponsor type
- Industry
- First posted
- Mar 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure the change in pain and function with subcutaneous injections of pentosan polysulfate sodium (PPS) compared with subcutaneous injections of placebo in participants with knee osteoarthritis pain. Study details include: * The study duration will be up to 31 weeks per participant * The treatment duration will be 6 weeks. * The visit frequency will be twice weekly during treatment. * The visit frequency will be every 4 weeks during the follow-up period.
Conditions
- Osteoarthritis, Knee
Interventions
Pentosan Polysulfate Sodium twice weeklyDrug
Subcutaneous Injection, 1.5mg/kg Ideal body Weight (IBW)
Placebo (Sodium Chloride Injection, 0.9%)Drug
Placebo to match PPS
Pentosan Polysulfate Sodium Fixed DoseDrug
Subcutaneous Injection, 100/150/180 mg if \<65kg/ ≥ 65 kg and ≤ 90kg/ \>90 kg IBW
Pentosan Polysulfate Sodium once weeklyDrug
Subcutaneous Injection, 2.0mg/kg Ideal body Weight (IBW)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline at Day 56 in knee pain as assessed by the average pain sub-scale score of the WOMAC® NRS 3.1 Index.Time frame: Baseline, Day 56
Locations
33 sites in 2 countries. Site status is shown where the registry gives one.
Alliance for Multispecialty Research - Tempe
Tempe, Arizona
Fiel Family and Sports Medicine
Tempe, Arizona
Tucson Orthopaedic Institute
Tucson, Arizona
Core Healthcare Group
Cerritos, California
Biosolutions Clinical Research Center
La Mesa, California
Providence Clinical Research
North Hollywood, California
Prospective Research Innovations Inc.
Rancho Cucamonga, California
Encompass Clinical Research
Spring Valley, California
Clinical Research of West Florida- Clearwater
Clearwater, Florida
University Clinical Research-Deland
DeLand, Florida
LMG Research
Miami, Florida
Well Pharma Medical Research, Corp.
Miami, Florida
Progressive Medical Research
Port Orange, Florida
Clinical Research of West Florida
Tampa, Florida
Conquest Research
Winter Park, Florida
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Alliance for Multispecialty Research - Newton
Newton, Kansas
Alliance for Multispecialty Research - Wichita West
Wichita, Kansas
Alliance for Multispecialty Research - Wichita East
Wichita, Kansas
Tandem Clinical Research
Marrero, Louisiana
Alliance for Multispecialty Research - Las Vegas
Las Vegas, Nevada
Kaplan Medical Research
Las Vegas, Nevada
Coastal Carolina Research Center
North Charleston, South Carolina
Alliance for Multispecialty Research - Knoxville
Knoxville, Tennessee
FutureSearch Trials - Austin
Austin, Texas
Clinical Investigations of Texas
Plano, Texas
Clinical Trials of Texas, Inc.
San Antonio, Texas
Diagnostics Research Group - Northwest San Antonio
San Antonio, Texas
Discovery Clinical Trials
San Antonio, Texas
Australian Clinical Research Network
Maroubra, New South Wales, Australia
Griffith University
Southport, Queensland, Australia
Sportsmed
Stepney, South Australia, Australia
Linear Clinical Research Limited
Nedlands, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.